Comparison of Clinical Outcomes POD L GF vs POD F GF (PHY1707)

Sponsor
Beaver-Visitec International, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT03688399
Collaborator
(none)
53
1
2
37.7
1.4

Study Details

Study Description

Brief Summary

Prospective, randomised, controlled, single-surgeon, single-center clinical study to compare the clinical outcomes of two trifocal IOLs differing in the dominance of additional power. The investigational device POD L GF shows dominance for the intermediate addition (+1.75 D), whereas the control device POD F GF shows dominance for the near addition (+3.5 D). Implantation of the IOLs is bilaterally.

Condition or Disease Intervention/Treatment Phase
  • Device: IOL implantation experimental
  • Device: IOL implantation comparator
N/A

Detailed Description

This is a prospective, randomised, controlled, single-surgeon, single-center clinical study whereby patients undergoing routine cataract surgery will have bilateral implantation of trifocal intraocular lenses. The patients will either be implanted with the hydrophobic IOL FineVision POD L GF or the hydrophobic IOL FineVision POD F GF (both lenses: (PhysIOL, Liège, Belgium).

The devices under investigation (FineVision POD L GF and POD F GF) are trifocal glistening-free acrylic intraocular lenses (IOLs) manufactured by the sponsor of this study PhysIOL sa/nv. Both consist of the same hydrophobic material. The main difference between the lenses is the dominance of additional power. The investigational device POD L GF shows dominance for the intermediate addition (+1.75 D), whereas the control device POD F GF shows dominance for the near addition (+3.5 D). The IOLs will be implanted as part of the routine cataract surgery on patients suffering from cataract development.

Subjects participating in the trial will attend a total of 10 study visits (1 preoperative, 2 operative and 7 postoperative) over a period of 6 months. Subjects would have the option for unscheduled visits if required medically.

Primary and secondary endpoint data will be collected at the 6 months follow up visit. Data analyses will be done after the last patient finished the final examination to support the study publication plan.

Study Design

Study Type:
Interventional
Actual Enrollment :
53 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Clinical Study to Compare Clinical Outcomes of Hydrophobic Trifocal IOLs FineVision POD F GF and FineVision POD L GF After Bilateral Implantation
Actual Study Start Date :
Jul 30, 2018
Actual Primary Completion Date :
Feb 1, 2021
Actual Study Completion Date :
Sep 21, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: IOL Implantation experimental

hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near

Device: IOL implantation experimental
Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near

Active Comparator: IOL Implantation Comparator

hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate

Device: IOL implantation comparator
Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate

Outcome Measures

Primary Outcome Measures

  1. Monocular Best Corrected Distance Visual Acuity (CDVA) under photopic light conditions. [3 months postoperative]

    No statistically significant difference between the two study groups on monocular CDVA at 3 months follow up visit. A significance level of 0.05 or lower (p < 0.05) will be considered statistically significant. CDVA is measured with ETDRS charts placed in 4m distance with best aided corrective glasses according to ISO 11979-7:2014.

Secondary Outcome Measures

  1. Manifested refraction [3 months postoperative]

    The manifested refraction is measured by means of a phoropter. The data contains values for sphere, cylinder and axis of cylinder according to ISO 11979-7:2014. This data will also be used to calculate the manifested refractive spherical equivalent (MRSE)

  2. Uncorrected Distance Visual Acuity (UDVA) under photopic light conditions [3 months postoperative]

    UDVA is measured with ETDRS charts placed in 4m distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly under photopic light conditions.

  3. Uncorrected Distance Visual Acuity (UDVA) under mesopic light conditions [6 months postoperative]

    UDVA is measured with ETDRS charts placed in 4m distance according to ISO 11979-7:2014. This assessment is done monocularly under mesopic light conditions.

  4. Corrected Distance Visual Acuity (CDVA) under photopic light conditions [3 months postoperative]

    CDVA is measured with ETDRS charts placed in 4m distance with best aided corrective glasses according to ISO 11979-7:2014. This assessment is done binocularly under photopic light conditions.

  5. Corrected Distance Visual Acuity (CDVA) under mesopic light conditions [6 months postoperative]

    CDVA is measured with ETDRS charts placed in 4m distance with best aided corrective glasses according to ISO 11979-7:2014. This assessment is done monocularly under mesopic light conditions.

  6. Distance Corrected Intermediate Visual Acuity at 70cm (DCIVA) under photopic light conditions [3 months postoperative]

    DCIVA is measured with ETDRS charts placed in 70cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly under photopic light conditions.

  7. Distance Corrected Intermediate Visual Acuity at 70cm (DCIVA) under mesopic light conditions [6 months postoperative]

    DCIVA is measured with ETDRS charts placed in 70cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly under mesopic light conditions.

  8. Uncorrected Intermediate Visual Acuity at 70cm (UIVA) under photopic light conditions [3 months postoperative]

    UIVA is measured with ETDRS charts placed in 70cm distance. The examination is done without corrective glasses and according to ISO 11979-7:2014. This assessment is done monocularly and binocularly under photopic light conditions.

  9. Uncorrected Intermediate Visual Acuity at 70cm (UIVA) under mesopic light conditions [6 months postoperative]

    UIVA is measured with ETDRS charts placed in 70cm distance. The examination is done without corrective glasses and according to ISO 11979-7:2014. This assessment is done monocularly under mesopic light conditions.

  10. Distance Corrected Near Visual Acuity at 35cm (DCNVA) under photopic light conditions [3 months postoperative]

    DCNVA is measured with ETDRS charts placed in 35cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly under photopic light conditions.

  11. Distance Corrected Near Visual Acuity at 35cm (DCNVA) under mesopic light conditions [6 months postoperative]

    DCNVA is measured with ETDRS charts placed in 35cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly under mesopic light conditions.

  12. Uncorrected Near Visual Acuity at 35cm (UNVA) under photopic light conditions [3 months postoperative]

    UNVA is measured with ETDRS charts placed in 35cm distance. The examination is done without corrective glasses and according to ISO 11979-7:2014. This assessment is done monocularly and binocularly under photopic light conditions.

  13. Uncorrected Near Visual Acuity at 35cm (UNVA) under mesopic light conditions [6 months postoperative]

    UNVA is measured with ETDRS charts placed in 35cm distance. The examination is done without corrective glasses and according to ISO 11979-7:2014. This assessment is done monocularly under mesopic light conditions.

  14. Contrast Sensitivity (monocular) [6 months postoperative]

    Contrast Sensitivity under photopic and mesopic light conditions

  15. Contrast Sensitivity (binocular) [3 months postoperative]

    Contrast Sensitivity under photopic and mesopic light conditions

  16. Questionnaire: Visual Functioning Questionnaire - 25 (VFQ-25, National Eye Institute) [3 months postoperative]

    Patient reported outcomes measures of a questionnaire to address the general patient satisfaction and possible side effects of the treatment. For this study, the validated and verified questionnaire VFQ-25 (National Eye Institute) will be used. This questionnaire consists of 25 questions. Each answer is scaled between a score of 0 and 100 according to a predefined calculation algorithm, with 100 always being the best possible outcome. Additionally subscales are calculated as an average value of several answers belonging to the same set of questions. The subscales are: General Health General Vision Ocular Pain Near Activities Distance Activities Social Functioning Mental Health Role Difficulties Dependancy Driving Color Vision Peripheral Vision

  17. Defocus Curve monocular [1 month postoperative]

    To assess the visual acuity for different distances, defocus curves under photopic and mesopic light conditions are measured. This test is performed with best distance corrected refraction and spherical additions ranging from -5.0 D to +1.5 D. This examination is performed monocularly.

  18. Defocus Curve binocular [3 months postoperative]

    To assess the visual acuity for different distances, defocus curves under photopic and mesopic light conditions are measured. This test is performed with best distance corrected refraction and spherical additions ranging from -5.0 D to +1.5 D. This examination is performed binocularly.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Cataractous eyes and/or patients suffering from presbyopia with no ocular comorbidity

  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures

  • Signed informed consent

Exclusion Criteria:
  • Age of patient <40 years

  • Irregular astigmatism

  • Regular corneal astigmatism >0.75 dioptres by an automatic keratometer or biometer or

1.0 dioptres if the steep axis of cylinder is between 90° and 120°

  • Difficulty for cooperation (distance from their home, general health condition)

  • Acute or chronic disease or illness that would increase risk or confound study results (e.g. diabetes mellitus (with retinopathy), immunocompromised, glaucoma etc…)

  • Any ocular comorbidity

  • History of ocular trauma or prior ocular surgery including refractive procedures

  • Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, chronic Uveitis, Marfan's syndrome)

  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions)

  • AMD suspicious eyes

  • Complicated surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Semmelweis University - Department of Ophthalmology Budapest Hungary 1085

Sponsors and Collaborators

  • Beaver-Visitec International, Inc.

Investigators

  • Principal Investigator: Zoltan Nagy, MD, Semmelweis University - Department of Ophthalmology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Beaver-Visitec International, Inc.
ClinicalTrials.gov Identifier:
NCT03688399
Other Study ID Numbers:
  • PHY1707
First Posted:
Sep 28, 2018
Last Update Posted:
Jan 11, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Beaver-Visitec International, Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 11, 2022